Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Photodynamic process induced by chloro-aluminum phthalocyanine nanoemulsion in glioblastoma

Full text
Author(s):
Castilho-Fernandes, Andrielle [1] ; Lopes, Tacila G. [1] ; Primo, Fernando L. [1] ; Pinto, Marcelo R. [1] ; Tedesco, Antonio C. [1]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Ctr Nanotechnol & Tissue Engn Photobiol & Photome, Dept Chem, Fac Filosofia Ciencias & Letras Ribeirao Preto, BR-14040901 Ribeirao Preto, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Photodiagnosis and Photodynamic Therapy; v. 19, p. 221-228, SEP 2017.
Web of Science Citations: 8
Abstract

Background: Glioblastoma multiforme (GBM) is a tumor characterized by rapid cell proliferation and migration. GBM constitutes the most aggressive and deadly type of brain tumor and is classified into several subtypes that show high resistance to conventional therapies. There are currently no curative treatments for malignant glioma despite the numerous advances in surgical techniques, radiotherapy, and chemotherapy. Therefore, alternative approaches are required to improve GBM treatment. Methods: Our study proposes the use of photodynamic therapy (PDT) for GBM treatment, which uses chloroaluminum phthalocyanine (AlClPc) encapsulated in a new drug delivery system (DDS) and designed as a nanoemulsion (AlClPc/NE). The optimal dark non-cytotoxic AlCIPc/NE concentration for the U87 MG glioma cell model and the most suitable laser light intensity for irradiation were determined. Experimental U87 MG cancer cells were analyzed via MTT cell viability assay. Cellular localization of AlClPc, morphological changes, and cell death via the necrotic and apoptotic pathways were also evaluated. Results: AlClPc remained in the cytoplasmic region at 24 h after administration. Additionally, treatment with 1.0 mu mol/L AlClPc under light irradiation at doses lower than 140 mJ/cm resulted in morphological changes with 50 +/- 6% cell death (p < 0.05). Moreover, 20 +/- 2% of U87 MG cells underwent cell death via the necrotic pathway. Measurement of Caspase-9 and -3 activities also suggested that cells underwent apoptosis. Taken together, these results indicate that AlClPc/NE-PDT can be used in the treatment of glioblastoma by inducing necrotic and apoptotic cell death. Conclusions: Our findings suggest that AlClPc/NE-PDT induces cell death in U87 MG cells in a dose-dependent manner and could thus serve as an effective adjuvant treatment for malignant glioma. AlClPc/NE-PDT utilizes a low dose of visible light and can be used in combination with other classic GBM treatment approaches, such as a combination of chemotherapy and surgery. (AU)

FAPESP's process: 16/21504-5 - Characterization and analysis of proteins-based nanoparticles with PcClAl and magnetic nanoparticle in association with hydrogel-based biopolymer to be used in the treatment of neurological diseases.
Grantee:Tácila Gabriele Lopes
Support type: Scholarships abroad - Research Internship - Master's degree
FAPESP's process: 13/50181-1 - Use of drugs containing nanocarriers with photosensitizers and/or other active compounds applied to cell therapy and treatment of central nervous system disorders
Grantee:Antonio Claudio Tedesco
Support type: Research Projects - Thematic Grants